HQ Function

Serves as a major hub for US clinical development, medical affairs, regulatory interactions with the FDA, and commercial strategy for North America. It supports the advancement of Orchard's gene therapy pipeline in the US.

Notable Features:

Located in Boston's Seaport District, a vibrant area known for its concentration of life science companies, research institutions, and access to top talent. The offices are typically modern and designed to foster collaboration.

Work Culture:

Prior to acquisition, Orchard Therapeutics was known for a culture focused on scientific innovation, patient-centricity, and a fast-paced environment driven by the urgency of developing treatments for rare diseases. Collaboration and a strong sense of mission were key characteristics.

HQ Significance:

Boston's ecosystem provides strategic advantages, including proximity to world-class academic and medical centers, a skilled workforce, and a supportive environment for biotech innovation. This location is critical for FDA engagement and US market access.

Values Reflected in HQ: The choice of Boston reflects a commitment to innovation, access to scientific excellence, and a strategic focus on one of the world's leading biotech clusters, aligning with values of pioneering science and patient impact.

Location:

Prior to its acquisition by Kyowa Kirin in early 2024, Orchard Therapeutics operated with a significant global presence, primarily centered in the US (Boston, MA and Menlo Park, CA) and the UK (London). These locations supported a wide range of functions including research and development, clinical trial management across multiple countries, regulatory affairs with global health authorities (FDA, EMA), manufacturing and supply chain logistics, and pre-commercial activities. Their global strategy focused on advancing their pipeline of gene therapies for rare diseases to patients worldwide.

Street Address:

100 Northern Avenue

City:

Boston

State/Province:

MA

Country:

USA